Table 2 Skin status at first evaluation examination
IM IFNβ-1a (n = 82) | SC IFNβ-1b (n = 123) | SC IFNβ-1a (n = 184) | SC GA (n = 23) | Overall (N = 412) | |
|---|---|---|---|---|---|
Any ISR, n (%) | 11 (13.4) | 71 (57.7) | 125 (67.9) | 7/23 (30.4) | 214 (51.9) |
Necrosis, n (%) | 0 (0)a | 7 (5.7) | 11 (6.0) | 0 (0) | 18 (4.4) |
Number of occurrences | |||||
1 | 0 | 1/7 (14.3) | 6/11 (54.5) | 0 | 7/18 (38.9) |
2 | 0 | 4/7 (57.1) | 3/11 (27.3) | 0 | 7/18 (38.9) |
3 | 0 | 1/7 (14.3) | 1/11 (9.1) | 0 | 2/18 (11.1) |
4 | 0 | 1/7 (14.3) | 0 | 0 | 1/18 (5.6) |
Unknown | 0 | 0 | 1/11 (9.1) | 0 | 1/18 (5.6) |
Severity | |||||
Mild | 0 | 3/7 (42.9) | 6/11 (54.5) | 0 | 9/18 (50.0) |
Moderate | 0 | 3/7 (42.9) | 3/11 (27.3) | 0 | 6/18 (33.3) |
Severe | 0 | 1/7 (14.3) | 1/11 (9.1) | 0 | 2/18 (11.1) |
Unknown | 0 | 0 | 1/11 (9.1) | 0 | 1/18 (5.6) |
Lipoatrophy, n (%) | 1 (1.2)b | 11 (8.9) | 19 (10.3) | 3 (13.0) | 34 (8.3) |
Number of occurrences | |||||
1 | 0 | 1/11 (9.1) | 5/19 (26.3) | 1/3 (33.3) | 7/34 (20.6) |
2 | 0 | 6/11 (54.5) | 6/19 (31.6) | 1/3 (33.3) | 13/34 (38.2) |
3 | 0 | 2/11 (18.2) | 2/19 (10.5) | 1/3 (33.3) | 5/34 (14.7) |
4 | 1/1 (100) | 0 | 0 | 0 | 1/34 (2.9) |
≥5 | 0 | 2/11 (18.2) | 6/19 (31.6) | 0 | 8/34 (23.5) |
Severity | |||||
Mild | 1/1 (100) | 6/11 (54.5) | 10/19 (52.6) | 2/3 (66.7) | 19.34 (55.9) |
Moderate | 0 | 2/11 (18.2) | 9/19 (47.4) | 1/3 (33.3) | 12/34 (35.3) |
Severe | 0 | 1/11 (9.1) | 0 | 0 | 1/34 (2.9) |
Unknown | 0 | 2/11 (18.2) | 0 | 0 | 2/34 (5.9) |
Injection omitted during last 4 weeks, n (%) | 0 (0)c | 7 (5.7) | 13 (7.1) | 1 (4.3) | 21 (5.1) |